Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales
description
Transcript of Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales
![Page 1: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/1.jpg)
Cost-effectiveness of paediatric seasonal influenza vaccination in
England and Wales
RJ PitmanICON Health Economics, Oxford, UK
Canadian Public Health Association Conference
Toronto, CanadaMay, 2014
![Page 2: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/2.jpg)
Why conduct cost-effectiveness analyses?
• Health policy is formulated to maximise the health of the population
• Budgets are finite
• So how do we most efficiently use these limited resources?
![Page 3: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/3.jpg)
Incremental costs and benefits
Choice : PolicyA or B ?
Cost
Costs OutcomesPolicy A
Costs OutcomesPolicy B
Benefit
Does the extra benefit justify the extra cost ?
![Page 4: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/4.jpg)
Cost-effectiveness plane
New treatment more effective
New treatment less effective
New treatment more costly
New treatment less costly
New treatment dominates
Old treatment dominates New treatment more costly and more effective
New treatment less costly and less effective
![Page 5: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/5.jpg)
Cost-effectiveness threshold £20,000 per QALY
QALYs gained
Cost
Cost-effectiveness and opportunity cost
£40,000Price = P*£20,000 per QALY
£60,000Price > P*£30,000 per QALY
2
£20,000Price < P*£10,000 per QALY
1
Net Health Benefit1 QALY
3
Net Health Benefit-1 QALY
![Page 6: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/6.jpg)
The region of cost-effectivenessDifference in cost
Difference in effect
Cost-eff
ective
ness th
reshold
Region of c
ost-eff
ective
ness
![Page 7: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/7.jpg)
Cost-effectiveness plane
0.0 0.2 0.4 0.6 0.8 1.0
050
0010
000
1500
020
000
QALYs
co
sts
l
l = cost-effectiveness threshold
![Page 8: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/8.jpg)
Cost effectiveness acceptability curvePr
obab
ility
mos
t cos
t-effe
ctive
Cost-effectiveness threshold (l)
100%
50%
20%
80%
New Treatment
Current Treatment
![Page 9: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/9.jpg)
Moving from the ICER to net benefit
Threshold defines value of health outcome
Standard ICER decision rule:ΔC/ΔQ < λ Where λ is the threshold
Net monetary benefit:(ΔQ x λ) – ΔC > 0
Net health benefit:ΔQ – (ΔC/ λ) > 0
![Page 10: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/10.jpg)
0 5000 10000 15000
-1.0
-0.5
0.0
0.5
1.0
costs
NH
BQ
Cmax lQ
![Page 11: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/11.jpg)
Influenza vaccinationIn England and Wales vaccination against seasonal influenza was only offered if:
• Over six months old and at an increased risk of influenza complications
• This included everyone over the age of 65 years and anyone younger who falls into a predefined risk group
![Page 12: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/12.jpg)
Influenza vaccination
• Base case
Influenza vaccination (status quo)• 6mo - <65yrs at risk of influenza related
complications• 65+yrs
vs
Paediatric influenza vaccination• Status quo + 2yrs - <19yrs
![Page 13: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/13.jpg)
The components of a vaccine cost-effectiveness model
Pitman et al. Vaccine (2012) 30: 1208-1224
![Page 14: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/14.jpg)
Who Acquires Infection From Whom (WAIFW) matrix
Mossong J et al. PLoS Med (2008) 5: 381-391
![Page 15: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/15.jpg)
The components of a communicable disease model
Vynnycky E et al. Vaccine (2008) 26: 5321-5330
![Page 16: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/16.jpg)
Deaths
Hospitalization
Outpatient visits
Primary care physician visits
Symptomatic disease
Influenza infections
Pitman et al. J Infect (2007) 54: 530-538
AH1N1 AH3N2 B(Yam) B(Vic)
![Page 17: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/17.jpg)
Incremental cost effectiveness analysis over 15 years, at 50% uptake
Policy option QALYs lost
(millions)
Cost (millions)
Incremental QALYs
(millions)
Incremental Cost
(millions)
ICER
No Vaccination 10.25 £8,123 Dominated
Current policy 2.43 £6,730 7.82 -£1,393 Cost saving
Current policy + vaccination in 2 - 4 year olds
1.75 £6,759 0.69 £29 £43
Current policy + vaccinationin 2 - 18 year olds
0.20 £7,870 1.55 £1,111 £719
![Page 18: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/18.jpg)
15 year cumulative burden of influenza, at 50% uptake
Current practice (CP)
CP + 2-4 yrs
No vaccination
CP + 2-18 yrs
Pitman et al. Vaccine (2013) 31: 927-942
![Page 19: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/19.jpg)
Cost effectiveness acceptability curves, using 15 year cumulative data, at 50%
No vaccination
Current policy
CP + 2-4 yrs
CP + 2-18 yrs
Pitman et al. Vaccine (2013) 31: 927-942
![Page 20: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/20.jpg)
Conclusions• Paediatric vaccination is likely to result in
substantial health savings both within and beyond the vaccinated cohorts of children
• While there is considerable uncertainty in the system, annual paediatric influenza vaccination was consistently estimated to be cost-effective
![Page 21: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/21.jpg)
Thank You
Contributors:
Lisa Nagy – ICON Health Economics
Mark Sculpher – York Centre for Health Economics
![Page 22: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/22.jpg)
Reserve slides
![Page 23: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/23.jpg)
Decisions when a treatment does not dominate
• Assessing the opportunity cost– What existing treatments will have to be displaced?– What health benefits will be forgone?
• A rule of thumb– How does the extra cost of a unit of benefit compare
with previous decisions?
• What is society willing to pay for an extra unit of benefit?– Increase insurance premiums/taxation to provide new intervention
![Page 24: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/24.jpg)
Influenza virus• Constantly changing virus• Comes in two types: A and B• Influenza A
– Responsible for pandemics– Has numerous subtypes
• A(H1N1) – 1918• A(H2N2) – 1957• A(H3N2) – 1968• A(H1N1/09) – 2009
PHIL ID #11823, Dan Higgins, CDC
![Page 25: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/25.jpg)
Burden of influenza in England & Wales
The annual health burden of seasonal influenza is considerable
Very roughly:
• 1 million General Practice consultations
• 25,000 Hospitalisations
• 20,000 Deaths
Pitman R et al, J Infect, 2007, 54, 530-538
![Page 26: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/26.jpg)
Estimated annual rate of influenza A relatedprimary care consultations
Pitman R et al, J Infect, 2007, 54, 530-538
![Page 27: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/27.jpg)
Estimated annual rate of influenza A relatedhospitalisations
Pitman R et al, J Infect, 2007, 54, 530-538
![Page 28: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/28.jpg)
Estimated annual rate of influenza A relateddeaths
Pitman R et al, J Infect, 2007, 54, 530-538
![Page 29: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/29.jpg)
The debate: Who should we be targeting?
• Those at greatest risk of complications?
• Or a combination of both?
• Those most likely to transmit the virus?
Influenza virion TEM: #10073 CDC/ Dr. Erskine. L. Palmer; Dr. M. L. Martin
![Page 30: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/30.jpg)
Objective
• To assess the cost effectiveness of adopting a policy of routine childhood influenza vaccination in the England and Wales, taking account of the dynamics of transmission and indirect protection (herd protection)
![Page 31: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/31.jpg)
SusceptibleImmune following infectionVaccinatedProtected by herd immunity
Herd Immunity
![Page 32: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/32.jpg)
Current policyHigh risk groups• 65+ years old• 6 months – 64 years old in the following groups:
– Residents of nursing or residential homes for the elderly and other long-stay facilities
– or with the following conditions:• Chronic respiratory disease (includes asthma treated with continuous or
repeated use of inhaled or systemic corticosteroids or asthma with previous exacerbations requiring hospital admission)
• Chronic heart, liver or renal disease• Chronic neurological disease• Diabetes mellitus• Immunosuppression because of disease or treatment • HIV infection (regardless of immune status)
– Carers of the above– Health care workers– Pregnant women
![Page 33: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/33.jpg)
Methods: Univariate sensitivity analysis• Population mixing
– Homogeneous (random)
• Basic reproductive rate– 1.4– 2.2
• No Seasonality
• Seeding– 10 / year / age band; 5 – 50 years of age
• Vaccine Coverage– 10%– 50%– 80%
![Page 34: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/34.jpg)
Status quo
• Elderly (65+yrs) and at risk groups vaccinated
• Annually from 2000 onwards
Age groups in
model%
efficacy 1
% uptake in total
population2
0 - <1 60% 0.1%
1 - <2 60% 0.1%
2 - <5 60% 1.4%
5 - <11 60% 1.4%
11 - <19 60% 1.4%
19 - <50 75% 5.6%
50 - <65 75% 5.6%
65+ 50% 73.5%1. Jefferson T. et al Cochrane Database Syst Rev, CD004879 2008
Jefferson T. et al Cochrane Database Syst Rev, CD001269 2007Rivetti, D. et al Cochrane Database Syst Rev, CD004876 2006
2. Health Protection Agency data
![Page 35: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/35.jpg)
Paediatric vaccination • Annually from 2009 onwards• Efficacy 80% 1,2
• Coverage 50%• Target age groups
– Pre-school: 2 - <5– Primary School age: 5 - <11– Secondary school age: 11-<19
1. Jefferson T. et al Cochrane Database Syst Rev, CD004879 2008Jefferson T. et al Cochrane Database Syst Rev, CD001269 2007Rivetti, D. et al Cochrane Database Syst Rev, CD004876 2006
2. Belshe, R. B. et al N Engl J Med, 2007, 356, 685-696Rhorer, J. et al Vaccine, 2009, 27, 1101-1110
![Page 36: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/36.jpg)
Cost-effectiveness analysis
![Page 37: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/37.jpg)
Assumptions
• Health Service (NHS) perspective
• 3.5% discount rate applied to both costs and benefits
![Page 38: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/38.jpg)
Costs• Vaccination
– GP consultation– Vaccine price point
• TIV – mean list price• LAIV = TIV
• Health outcomes – age stratified mean cost of influenza related– GP consultation– Hospitalisation
• Costs inflated to 2009 prices, where appropriate
![Page 39: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/39.jpg)
Outcomes
• Averted– General practice consultations– Hospitalisations– Deaths
• Quality adjusted life years– QALY decrements based on estimates from 2003 HTA
report1
– Adult QALYs used
1. Turner D et al Health Technol Assess. 2003; 7: 1-170
![Page 40: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/40.jpg)
Sensitivity analyses
• Univariate sensitivity analysis• Probabilistic Sensitivity analysis
– Variation in probabilities: beta distribution– Variation in costs and utility decrements: gamma
distribution– Probability cost-effective: Cost-effectiveness acceptability
curve (CEAC)– Probability of option with highest net benefit being cost-
effective: Cost-effectiveness acceptability frontier (CEAF)• Extreme value analysis
![Page 41: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/41.jpg)
Extreme Value Analysis• The transmission coefficient (R0 of 1.4, 1.8 and 2.2)• Infectious cases seeded into the population each
year (50, 100, 150)• Duration of natural immunity (influenza A: 5 years, 6
years, 7 years; influenza B: 11 years, 12 years, 13 years)
• Duration of infectiousness (1 day, 2 days, 5 days)• Percentage of infected individuals that experience
symptoms (55%, 64%, 73%)• Latent period (1 day, 2 days, 3 days)• Duration of vaccine induced immunity (Flu A: 3
years, 6 years, 7 years; Flu B: 6 years, 12 years, 13 years)
![Page 42: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/42.jpg)
Simulated influenza Vaccination of elderly
Paediatric vaccination
![Page 43: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/43.jpg)
Results: Sensitivity of the 15 year cumulative averted influenza cases per 100,000 population,
assuming 80% coverage of 2 to 18 year old children with LAIV in addition to current practice
![Page 44: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/44.jpg)
Extreme value analysis
Influenza A Influenza B
![Page 45: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/45.jpg)
The cost of an influenza related GP consultation
General Practice Research Database 2000 - 2009Personal and Social Services Research Group Report 2008
Age Group GP consultations0-11 mo £8812-23 mo £8824-59 mo £655-10 years £5411-18 years £6619-49 years £8550-64 years £10165+ years £100
![Page 46: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/46.jpg)
MedianMedian
CostLengthof Stay
0 - 10 yr 6 1,606
11 - 18 yr 6 1,634
19 - 49 yr 6 1,662
50 - 64 yr 7 1,983
65+ yr 19 5,354
All Ages 8 2,123
The cost of an influenza related hospitalisation
Hospital Episode Statistics 2005-06NHS National Schedule of Reference Costs 2007-08
![Page 47: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/47.jpg)
Annual primary care and hospitalisation costs of influenza in England & Wales
Total annual cost ~ £175,000,000
Hospital Episode Statistics 2005-06NHS National Schedule of Reference Costs 2007-08General Practice Research DatabasePerson and Social Services Research Unit annual reportPitman R et al, J Infect, 2007, 54, 530-538
![Page 48: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/48.jpg)
Results: Sensitivity of ICER to time horizon, at 50% uptake
![Page 49: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/49.jpg)
15 year estimated cumulative burden of influenza, at increasing levels of paediatric
vaccine uptake
![Page 50: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/50.jpg)
Cost effectiveness acceptability frontier, based on 15 year cumulative data, at 50% uptake
![Page 51: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/51.jpg)
Limitations
• Model incidence calibrated against Tecumseh data (1970s, US data)
• It was not possible to benchmark the model simulations against actual European data on influenza virus infection rates. Obtaining such sero-epidemiological data will help reduce uncertainty within the parameter estimates
• High level of uncertainty in many of the parameters
• Vaccination behaviour
• Simple treatment of antigenic drift
• Cross-protection
![Page 52: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/52.jpg)
Is there evidence for herd immunity?
![Page 53: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/53.jpg)
Tecumseh, Michigan, USA
1968
HONG KONG FLUAH3N2
![Page 54: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/54.jpg)
Tecumseh studyTecumseh• Population ~10,000• Respiratory illness surveillance
project since 1965• ~360 families followed at any one
time– 60% random selection– 40% selected with chronic respiratory
disease & matched controls– Followed for one year then replaced
with another family• Vaccinated 85.8% school age children
(Elementary through to High School)• Monovalent vaccine (A2/Aichi/2/68)
vs. AH3N2 virus (Hong Kong Flu)• School absenteeism monitored along
with respiratory illness surveillance
Adrian• Population ~20,000• 12 miles south of Tecumseh• Significant population interchange• Weekly family surveillance
programme in place• 150 households• Each family followed for 3 weeks• Same questions on respiratory illness
as in Tecumseh• School absence data also collected
Monto AS et al, Bull World Health Organ, 1969, 41, 537-542
![Page 55: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/55.jpg)
Tecumseh study
Two weeks after vaccination began the first isolate of AH3N2 was obtained in Tecumseh
![Page 56: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/56.jpg)
School absenteeism 1968 – ‘69
Monto AS et al, Bull World Health Organ, 1969, 41, 537-542
![Page 57: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/57.jpg)
Incidence of respiratory illness
Monto AS et al, Bull World Health Organ, 1969, 41, 537-542
![Page 58: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/58.jpg)
Age specific weekly mean rate of respiratory illness
0 - 4 5 - 9 10 - 14 15 - 19 20 - 29 30 - 39 40+02468
1012141618 Adrian (adjusted)
Tecumseh
Age group (Years)
Perc
enta
ge p
er w
eek
(Mea
n)
85.8% vaccine coverage
Monto AS et al, J Infect Dis, 1970, 122, 16-25
![Page 59: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/59.jpg)
Japan – paediatric influenza vaccination
• 1962 – 1987 mandatory influenza vaccination of all schoolchildren
• Law relaxed in 1987• Repealed in 1994• Thomas Reichert analysed excess mortality
1949 - 1998
Reichert et al. N Eng J Med 2001;344:889-896
![Page 60: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/60.jpg)
Excess deaths attributed to pneumonia and influenza – 5 year moving average
Reichert et al. N Eng J Med 2001;344:889-896
![Page 61: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/61.jpg)
Population pyramid, Japan, 1950 - 2000
AgeMale Female Male Female1950 2000
Population (thousands) Population (thousands)
![Page 62: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/62.jpg)
Herd immunity demonstrated in randomised control trial in 2010
Loeb et al. JAMA 2010; 303: 943-950
![Page 63: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/63.jpg)
![Page 64: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/64.jpg)
A simple epidemic schematic with replenishment of susceptible individuals
Time
Infe
ction
s
0
= R0
Epidemic curve
Effec
tive
repr
oduc
tive
rate
0
2
1
Effective reproductive rate
![Page 65: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/65.jpg)
Communicable disease epidemiology
Time
Infe
ction
s
0
Epidemic curve
Effec
tive
repr
oduc
tive
rate
0
2
1
Effective reproductive rate
Imm
une
S
Vaccination
![Page 66: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/66.jpg)
Communicable disease epidemiology
Time
Infe
ction
s
0
Effec
tive
repr
oduc
tive
rate
0
2
1
Imm
une
SV
Vaccination
Epidemic curveEffective reproductive rate
![Page 67: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/67.jpg)
Communicable disease epidemiology
Time
Infe
ction
s
0
Effec
tive
repr
oduc
tive
rate
0
2
1
Imm
une
SV
Vaccination
Epidemic curveEffective reproductive rate
![Page 68: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/68.jpg)
Communicable disease epidemiology
Time
Infe
ction
s
0
Effec
tive
repr
oduc
tive
rate
0
2
1
Imm
une
SV
Vaccination
Epidemic curveEffective reproductive rate
![Page 69: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/69.jpg)
Communicable disease epidemiology
Time
Infe
ction
s
0
Effec
tive
repr
oduc
tive
rate
0
2
1
Imm
une
SV
Vaccination
Epidemic curveEffective reproductive rate
![Page 70: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/70.jpg)
Communicable disease epidemiology
Time
Infe
ction
s
0
Effec
tive
repr
oduc
tive
rate
0
2
1
Imm
une
SV
Vaccination
Epidemic curveEffective reproductive rate
![Page 71: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/71.jpg)
Replenishment of susceptibles
Generation of immunity
• Rate of viral spread• R0
• Viral generation time• Vaccination
• Coverage • Frequency• Behaviour
• Loss of effective immunity• Waning immunity• Antigenic drift / shift
• Births
![Page 72: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/72.jpg)
QALYs
• “Generic” measure of health– Applicable to a wide range of clinical areas
• Combines length and quality of life• Utilities used as quality weights:
– Survival = 10 years– Utility score = 0.5– QALYs = 10 x 0.5 = 5 QALYs
![Page 73: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/73.jpg)
Calculation Of QALYsUTILITY
YEARS321
0.9
0.5
4
1 QALY(No treatment)
3.6 QALYs(With treatment)
2.6 QALYs gained
![Page 74: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/74.jpg)
Calculation Of QALYs
YEARS
UTILITY
15105
0.9
0.5
No Treatment
With Treatment
QALYs Gained
![Page 75: Cost-effectiveness of paediatric seasonal influenza vaccination in England and Wales](https://reader036.fdocuments.us/reader036/viewer/2022062323/56816326550346895dd39f85/html5/thumbnails/75.jpg)
A QALY Is A QALYUTILITY
YEARS321
1
0.5
0.3